About The Study: In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful progression-free survival benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life.
Corresponding Author: To contact the corresponding author, Binghe Xu, MD, PhD, email xubinghe@medmail.com.cn .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2026.1938)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1938?guestAccessKey=0e5d2d89-1a45-417a-9249-c906ea9ab814&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126
JAMA Oncology